IMMUNITYBIO, INC. Amortization of Intangible Assets
IMMUNITYBIO, INC. (IBRX) reported Amortization of Intangible Assets of $500.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2025-08-05
- IMMUNITYBIO, INC. amortization of intangible assets for the quarter ending 2025-06-30 was $500.00K, a 0.00% change year-over-year.
- IMMUNITYBIO, INC. amortization of intangible assets for the quarter ending 2025-03-31 was $500.00K, a 0.00% change year-over-year.
- IMMUNITYBIO, INC. amortization of intangible assets for the quarter ending 2024-12-31 was $500.00K, a 0.00% change year-over-year.
- IMMUNITYBIO, INC. amortization of intangible assets for the quarter ending 2024-09-30 was $500.00K, a 0.00% change year-over-year.
- IMMUNITYBIO, INC. amortization of intangible assets for fiscal 2024 was $2.00M, a 0.00% change from fiscal 2023.
- IMMUNITYBIO, INC. amortization of intangible assets for fiscal 2023 was $2.00M, a 5.26% increase from fiscal 2022.
- IMMUNITYBIO, INC. amortization of intangible assets for fiscal 2022 was $1.90M.
- IMMUNITYBIO, INC. amortization of intangible assets for fiscal 2018 was $2.30M, a 0.00% change from fiscal 2017.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2025-06-30 | $500.00K 10-Q · filed 2025-08-05 | $1.00M 10-Q · filed 2025-08-05 | $1.50M derived: sum of 3 quarters · filed 2025-08-05 | $2.00M derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | $500.00K 10-Q · filed 2025-05-12 | $1.00M derived: sum of 2 quarters · filed 2025-05-12 | $1.50M derived: sum of 3 quarters · filed 2025-05-12 | $2.00M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.00M derived: sum of 2 quarters · filed 2025-03-03 | $1.50M derived: sum of 3 quarters · filed 2025-08-05 | $2.00M 10-K · filed 2025-03-03 |
| 2024-09-30 | $500.00K 10-Q · filed 2024-11-12 | $1.00M derived: sum of 2 quarters · filed 2025-08-05 | $1.50M 10-Q · filed 2024-11-12 | $2.00M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-06-30 | $500.00K 10-Q · filed 2025-08-05 | $1.00M 10-Q · filed 2025-08-05 | $1.50M derived: sum of 3 quarters · filed 2025-08-05 | $2.00M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-12 | $1.00M derived: sum of 2 quarters · filed 2025-05-12 | $1.50M derived: sum of 3 quarters · filed 2025-05-12 | $2.00M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.00M derived: sum of 2 quarters · filed 2025-03-03 | $1.50M derived: sum of 3 quarters · filed 2025-03-03 | $2.00M 10-K · filed 2025-03-03 |
| 2023-09-30 | $500.00K 10-Q · filed 2024-11-12 | $1.00M derived: sum of 2 quarters · filed 2024-11-12 | $1.50M 10-Q · filed 2024-11-12 | $2.00M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-12 | $1.00M 10-Q · filed 2024-08-12 | $1.50M derived: sum of 3 quarters · filed 2025-03-03 | $2.10M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-09 | $1.00M derived: sum of 2 quarters · filed 2025-03-03 | $1.60M derived: sum of 3 quarters · filed 2025-03-03 | $2.20M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.10M derived: sum of 2 quarters · filed 2025-03-03 | $1.70M derived: sum of 3 quarters · filed 2025-03-03 | $1.90M 10-K · filed 2025-03-03 |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-09 | $1.20M derived: sum of 2 quarters · filed 2023-11-09 | $1.40M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-08 | $900.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $300.00K 10-Q · filed 2023-05-11 | |||
| 2019-12-31 | $0.00 derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | $0.00 derived: sum of 2 quarters · filed 2021-04-22 | $0.00 derived: sum of 3 quarters · filed 2021-04-22 | $600.00K 8-K/A · filed 2021-04-22 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $600.00K 10-Q · filed 2019-11-05 | $1.20M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-06 | $600.00K 10-Q · filed 2019-08-06 | $1.20M derived: sum of 3 quarters · filed 2021-03-04 | $1.80M derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-03-31 | $600.00K 10-Q · filed 2019-05-08 | $1.20M derived: sum of 2 quarters · filed 2021-03-04 | $1.80M derived: sum of 3 quarters · filed 2021-03-04 | $2.40M derived: sum of 4 quarters · filed 2021-03-04 |
| 2018-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $1.20M derived: sum of 2 quarters · filed 2021-03-04 | $1.80M derived: sum of 3 quarters · filed 2021-03-04 | $2.30M 10-K · filed 2021-03-04 |
| 2018-09-30 | $600.00K 10-Q · filed 2019-11-05 | $1.20M derived: sum of 2 quarters · filed 2019-11-05 | $1.70M 10-Q · filed 2019-11-05 | $2.40M derived: sum of 4 quarters · filed 2020-03-25 |
| 2018-06-30 | $600.00K 10-Q · filed 2019-08-06 | $1.10M 10-Q · filed 2019-08-06 | $1.80M derived: sum of 3 quarters · filed 2020-03-25 | $2.40M derived: sum of 4 quarters · filed 2020-03-25 |
| 2018-03-31 | $600.00K 10-Q · filed 2019-05-08 | $1.20M derived: sum of 2 quarters · filed 2020-03-25 | $1.80M derived: sum of 3 quarters · filed 2020-03-25 | $2.40M derived: sum of 4 quarters · filed 2020-03-25 |
| 2017-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $1.20M derived: sum of 2 quarters · filed 2020-03-25 | $1.80M derived: sum of 3 quarters · filed 2020-03-25 | $2.30M 10-K · filed 2020-03-25 |
| 2017-09-30 | $600.00K 10-Q · filed 2018-11-07 | $1.20M derived: sum of 2 quarters · filed 2018-11-07 | $1.70M 10-Q · filed 2018-11-07 | $3.10M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-06-30 | $600.00K 10-Q · filed 2018-08-06 | $1.10M 10-Q · filed 2018-08-06 | $2.50M derived: sum of 3 quarters · filed 2019-03-13 | $2.90M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-03-31 | $600.00K 10-Q · filed 2018-05-07 | $1.90M derived: sum of 2 quarters · filed 2019-03-13 | $2.30M derived: sum of 3 quarters · filed 2019-03-13 | $2.80M derived: sum of 4 quarters · filed 2019-03-13 |
| 2016-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $1.70M derived: sum of 2 quarters · filed 2019-03-13 | $2.20M derived: sum of 3 quarters · filed 2019-03-13 | $2.60M 10-K · filed 2019-03-13 |
| 2016-09-30 | $400.00K 10-Q · filed 2017-11-07 | $900.00K derived: sum of 2 quarters · filed 2017-11-07 | $1.30M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $500.00K 10-Q · filed 2017-08-07 | $900.00K 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | $400.00K 10-Q · filed 2017-05-08 | |||
| 2015-12-31 | $1.30M 10-K · filed 2018-03-12 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |